Article
[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer.
European journal of nuclear medicine and molecular imaging - 1 Apr 2020
van Helden E J, Elias S G, Gerritse S L, van Es S C, Boon E, Huisman M C, van Grieken N C T, Dekker H, van Dongen G A M S, Vugts D J, Boellaard R, van Herpen C M L, de Vries E G E, Oyen W J G, Brouwers A H, Verheul H M W, Hoekstra O S, Menke-van der Houven van Oordt C W
Abstract excerpt
PURPOSE: One-third of patients with RAS wild-type mCRC do not benefit from anti-EGFR monoclonal antibodies. This might be a result of variable pharmacokinetics and insufficient tumor targeting. We evaluated cetuximab tumor accumulation on [89Zr]Zr-cetuximab PET/CT as a potential predictive biomarker and determinant for an escalating dosing strategy. PATIENTS AND METHODS: PET/CT imaging of [89Zr]Zr-cetuximab (37...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.